[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"doc-seo-341191-105":3,"detail-sidebar-cat-0-en-105":85,"doc-detail-341191-en":134},{"code":4,"msg":5,"data":6},0,"ok",{"site_id":7,"language":8,"slug":9,"title":10,"keywords":11,"description":12,"schema_data":13,"social_meta":78,"head_meta":80,"extra_data":82,"updated_unix":84},105,"en","cyclin-dependent-kinase-12-deficiency-reprogrammes-cellular-metabolism-to-alleviate-ferroptosis-potential-and-promote-the-progression-of-castration-resistant-prostate-cancer-research-article","Cyclin-dependent kinase 12 deficiency reprogrammes cellular metabolism to alleviate ferroptosis potential and promote the progression of castration-resistant prostate cancer - Research Article","","Cyclin-dependent kinase 12 (CDK12)-deficient prostate cancer is a castration-resistant prostate cancer subtype with poor prognosis, limited response to current therapies such as PARP inhibitors, and unclear mechanisms. Bioinformatics analyses and CRISPR-Cas9 with mass-spectrometry metabolomics define metabolic features and patient outcome links. Cell RNA-seq, ROS probes, mitochondrial assays, ChIP-qPCR, and RNA stability studies clarify CDK12’s role in mitochondrial regulation and ferroptosis. In vitro and in vivo studies identify ETC inhibitor IACS-010759 as a therapeutic option for CDK12-deficient CRPC.",{"@graph":14,"@context":77},[15,34,56],{"@type":16,"itemListElement":17},"BreadcrumbList",[18,23,27,31],{"item":19,"name":20,"@type":21,"position":22},"https://docshare.wps.com","Home","ListItem",1,{"item":24,"name":25,"@type":21,"position":26},"https://docshare.wps.com/document/","Document",2,{"item":28,"name":29,"@type":21,"position":30},"https://docshare.wps.com/document/research-report/","Research & Report",3,{"item":32,"name":10,"@type":21,"position":33},"https://docshare.wps.com/document/cyclin-dependent-kinase-12-deficiency-reprogrammes-cellular-metabolism-to-alleviate-ferroptosis-potential-and-promote-the-progression-of-castration-resistant-prostate-cancer-research-article/341191/",4,{"url":32,"name":10,"@type":35,"image":36,"author":41,"headline":10,"publisher":44,"fileFormat":47,"inLanguage":8,"description":12,"dateModified":48,"datePublished":49,"encodingFormat":47,"isAccessibleForFree":50,"interactionStatistic":51},"DigitalDocument",{"url":37,"@type":38,"width":39,"height":40},"https://docshare.wps.com/thumbnails/cyclin-dependent-kinase-12-deficiency-reprogrammes-cellular-metabolism-to-alleviate-ferroptosis-potential-and-promote-the-progression-of-castration-resistant-prostate-cancer-research-article/341191.png","ImageObject",300,407,{"name":42,"@type":43},"Ivy","Person",{"url":19,"name":45,"@type":46},"DocShare","Organization","application/pdf","2026-10-29","2026-09-22",true,{"@type":52,"interactionType":53,"userInteractionCount":55},"InteractionCounter",{"@type":54},"ViewAction",9,{"@type":57,"mainEntity":58},"FAQPage",[59,65,69,73],{"name":60,"@type":61,"acceptedAnswer":62},"What defines CDK12-deficient prostate cancer in this study?","Question",{"text":63,"@type":64},"The study describes CDK12-deficient prostate cancer as a subtype of castration-resistant prostate cancer with poor prognosis and limited efficacy from existing treatments such as PARP inhibitors.","Answer",{"name":66,"@type":61,"acceptedAnswer":67},"How did the researchers investigate metabolic changes caused by CDK12 loss?",{"text":68,"@type":64},"They combined bioinformatics with CRISPR-Cas9 and mass-spectrometry-based metabolomic profiling, and then used cell RNA-seq plus molecular assays to characterize metabolic and mitochondrial changes.",{"name":70,"@type":61,"acceptedAnswer":71},"What mechanism links CDK12 deficiency to ferroptosis?",{"text":72,"@type":64},"The study uses multiple assays (including ROS probes and mitochondrial function tests) to clarify how CDK12 regulates mitochondrial function and contributes to ferroptosis.",{"name":74,"@type":61,"acceptedAnswer":75},"Which therapeutic strategy showed effects in CDK12-deficient CRPC?",{"text":76,"@type":64},"In vitro drug sensitivity testing and mouse in vivo experiments identified the electron transport chain inhibitor IACS-010759 as having therapeutic effects in CDK12-deficient CRPC.","https://schema.org",{"og:url":32,"og:type":79,"og:title":10,"og:site_name":45,"og:description":12},"article",{"robots":81,"canonical":32},"index,follow",{"doc_id":83,"site_id":7},341191,1790722118,{"code":4,"msg":86,"data":87},"success",[88,92,96,100,105,110,115,119,123,126,130],{"id":22,"doc_module":4,"doc_module_name":25,"category_name":89,"show_sort_weight":90,"slug":91},"Story & Novel",90,"story-novel",{"id":26,"doc_module":4,"doc_module_name":25,"category_name":93,"show_sort_weight":94,"slug":95},"Literature",80,"literature",{"id":33,"doc_module":4,"doc_module_name":25,"category_name":97,"show_sort_weight":98,"slug":99},"Exam",70,"exam",{"id":101,"doc_module":4,"doc_module_name":25,"category_name":102,"show_sort_weight":103,"slug":104},5,"Comic",60,"comic",{"id":106,"doc_module":4,"doc_module_name":25,"category_name":107,"show_sort_weight":108,"slug":109},6,"Technology",50,"technology",{"id":111,"doc_module":4,"doc_module_name":25,"category_name":112,"show_sort_weight":113,"slug":114},7,"Healthcare",40,"healthcare",{"id":116,"doc_module":4,"doc_module_name":25,"category_name":29,"show_sort_weight":117,"slug":118},8,30,"research-report",{"id":55,"doc_module":4,"doc_module_name":25,"category_name":120,"show_sort_weight":121,"slug":122},"Religion & Spirituality",20,"religion-spirituality",{"id":121,"doc_module":4,"doc_module_name":25,"category_name":124,"show_sort_weight":121,"slug":125},"World Cup","world-cup",{"id":127,"doc_module":4,"doc_module_name":25,"category_name":128,"show_sort_weight":127,"slug":129},10,"Lifestyle","lifestyle",{"id":131,"doc_module":4,"doc_module_name":25,"category_name":132,"show_sort_weight":101,"slug":133},19,"General","general",{"code":4,"msg":86,"data":135},{"doc_id":83,"user_id":136,"nickname":42,"user_avatar":137,"doc_module":4,"category_id":116,"category_name":29,"doc_title":10,"doc_description":12,"doc_content":138,"file_id":139,"file_url":140,"file_type":141,"file_size":142,"view_count":55,"is_deleted":4,"is_public":22,"is_downloadable":22,"audit_status":22,"page_count":143,"language":144,"language_code":8,"site_id":7,"html_lang":8,"table_of_contents":145,"faqs":146,"seo_title":147,"seo_description":12,"update_tm":148,"read_time":149,"preview_page_count":33,"preview_urls":150},549758252649,"https://ap-avatar.wpscdn.com/avatar/8000253669c5317157?_k=1778319167496531819","DOI: 10.1002/ctm2.1678  \nRESEARCH ARTICLE  \nCyclin-dependent kinase 12 deficiency reprogrammes cellular metabolism to alleviate ferroptosis potential and promote the progression of castration-resistant prostate cancer  \nHaozhe Zhang1 Zengzhen Xing1  \n Yi Zhou1  Yating Feng1  Wenli Hou2  Yifan Zhang2  Qiang Wei2   Yu Yin3  \nYafei Chen1 Ju Guo4  \nHailiang Hu1, 5   \n1 Department of Biochemistry, School of Medicine, Southern University of Science and Technology, Shenzhen, China  \n2 Department of Urology, Nanfang Hospital, Southern Medical University, Guangzhou, China  \n3 Department of Pathology, The First Affiliated Hospital of Anhui Medical University, Hefei, China  \n4 Department of Urology, The First Affiliated Hospital of Nanchang University, Nanchang, China  \n5 Key University Laboratory of Metabolism and Health of Guangdong, Southern University of Science and Technology, Shenzhen, China  \nCorrespondence  \nYu Yin, Department of Pathology, The First Affiliated Hospital of Anhui Medical University, 230022 Hefei, China. [Email:](Email: yinyu@ahmu.edu.cn)[ yinyu@ahmu.edu.cn](Email: yinyu@ahmu.edu.cn)  \nJu Guo, Department of Urology, The First Affiliated Hospital of Nanchang University, 330006 Nanchang, China. [Email:](Email: Ndyfy02371@ncu.edu.cn)[ Ndyfy02371@ncu.edu.cn](Email: Ndyfy02371@ncu.edu.cn)  \nHailiang Hu, Department of Biochemistry, School of Medicine, Southern University of Science and Technology, 518055 Shenzhen, China.  \n[Email:](Email: huhl@sustech.edu.cn)[ huhl@sustech.edu.cn](Email: huhl@sustech.edu.cn)  \nGraphical Abstract  \nClin. Transl. Med. 2024;14:e1678 .  \n[https://doi.org/10.1002/ctm2.1678](https://doi.org/10.1002/ctm2.1678)  \n[wileyonlinelibrary.com/journal/ctm2](wileyonlinelibrary.com/journal/ctm2)  \nZHANG et al.  \n∙ CDK12 deficiency reprograms prostate tumor cell metabolism, promotes tumor progression while demonstrating therapeutic targets.  \n∙ Identified the regulation ofCDK12 on ACSL4 expression as a novel mechanism for controlling ferroptosis.  \nDOI: 10.1002/ctm2.1678  \nRESEARCH ARTICLE  \nCyclin-dependent kinase 12 deficiency reprogrammes cellular metabolism to alleviate ferroptosis potential and promote the progression of castration-resistant prostate cancer  \nHaozhe Zhang1 Zengzhen Xing1 Hailiang Hu1, 5   \n Yi Zhou1  Yating Feng1  Wenli Hou2  Yifan Zhang2  Qiang Wei2   Yu Yin3  \nYafei Chen1 Ju Guo4  \n1 Department of Biochemistry, School of Medicine, Southern University of Science and Technology, Shenzhen, China  \n2 Department of Urology, Nanfang Hospital, Southern Medical University, Guangzhou, China  \n3 Department of Pathology, The First Affiliated Hospital of Anhui Medical University, Hefei, China  \n4 Department of Urology, The First Affiliated Hospital of Nanchang University, Nanchang, China  \n5 Key University Laboratory of Metabolism and Health of Guangdong, Southern University of Science and Technology, Shenzhen, China  \nCorrespondence  \nYu Yin, Department of Pathology, The First Affiliated Hospital of Anhui Medical University, 230022 Hefei, China. [Email:](Email: yinyu@ahmu.edu.cn)[ yinyu@ahmu.edu.cn](Email: yinyu@ahmu.edu.cn)  \nJu Guo, Department of Urology, The First Affiliated Hospital of Nanchang University, 330006 Nanchang, China. [Email:](Email: Ndyfy02371@ncu.edu.cn)[ Ndyfy02371@ncu.edu.cn](Email: Ndyfy02371@ncu.edu.cn)  \nHailiang Hu, Department of Biochemistry, School of Medicine, Southern University of Science and Technology, 518055 Shenzhen, China. [Email:](Email: huhl@sustech.edu.cn)[ huhl@sustech.edu.cn](Email: huhl@sustech.edu.cn)  \nFunding information  \nNational Natural Science Foundation of China, Grant/Award Numbers: 82173131, 81972414, 82260500; Science and Technology Innovation Commission of Shenzhen Municipal Government Grants, Grant/Award Number: JCYJ20210324104007022; Natural Science Foundation of Guangdong Province,  \nAbstract  \nBackground: Cyclin-dependent kinase 12 (CDK12)-deficient prostate cancer defines a subtype of castration-resistant prostate cancer (CRPC) with a p","cbCaijGplRRDKrRF","https://ap.wps.com/l/cbCaijGplRRDKrRF","pdf",7450178,23,"English","# Background\n## CDK12-deficient prostate cancer subtype and treatment limitations\n# Methods\n## Bioinformatics, CRISPR-Cas9, metabolomics, and molecular assays\n## RNA-seq, ROS and mitochondrial function analyses, ChIP-qPCR, RNA stability\n## Drug sensitivity and mouse in vivo experiments\n# Results\n## Energy metabolism reprogramming and ETC inhibitor therapeutic effects","[{\"question\":\"What defines CDK12-deficient prostate cancer in this study?\",\"answer\":\"The study describes CDK12-deficient prostate cancer as a subtype of castration-resistant prostate cancer with poor prognosis and limited efficacy from existing treatments such as PARP inhibitors.\"},{\"question\":\"How did the researchers investigate metabolic changes caused by CDK12 loss?\",\"answer\":\"They combined bioinformatics with CRISPR-Cas9 and mass-spectrometry-based metabolomic profiling, and then used cell RNA-seq plus molecular assays to characterize metabolic and mitochondrial changes.\"},{\"question\":\"What mechanism links CDK12 deficiency to ferroptosis?\",\"answer\":\"The study uses multiple assays (including ROS probes and mitochondrial function tests) to clarify how CDK12 regulates mitochondrial function and contributes to ferroptosis.\"},{\"question\":\"Which therapeutic strategy showed effects in CDK12-deficient CRPC?\",\"answer\":\"In vitro drug sensitivity testing and mouse in vivo experiments identified the electron transport chain inhibitor IACS-010759 as having therapeutic effects in CDK12-deficient CRPC.\"}]","Cyclin-dependent kinase 12 deficiency reprogrammes cellular metabolism to alleviate ferroptosis potential and promote the progression of castration-resistant prostate cancer - Research Article | PDF",1790040811,58,[151,155,159,163],{"page_no":22,"url":152,"width":153,"height":154},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/58cf46f9879fee468c6a56e3976a374d.webp",983,1291,{"page_no":26,"url":156,"width":157,"height":158},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/f3f3328588cdb3bb5075359d80f5a4d6.webp",982,1290,{"page_no":30,"url":160,"width":161,"height":162},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/5ff34ff07a72b697003f795f68f64701.webp",981,1289,{"page_no":33,"url":164,"width":165,"height":166},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/922f99d4abd9e2ca041d03fc6e24ca61.webp",980,1287]